Navigation Links
CT texture analysis of tumors may be a valuable biomarker in localized esophageal cancer
Date:2/8/2013

Orlando, Fla., February 8, 2013 CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

This study evaluated the tumoral texture analysis on baseline and post-treatment CT scans of 31 patients with localized resectable esophageal cancer patients with a median age of 63 and who received neoadjuvant chemotherapy between 2007 and 2010. CT scans were performed before and after the use of chemotherapy and prior to surgery. All patients received platinum and fluorouracil-based chemotherapy followed by surgery. Texture parameters (mean-grey level intensity (MGI), entropy, uniformity, kurtosis, skewness and standard deviation of histogram (SDH)) were derived for four filter values to highlight structures of different spatial width: 1.0 (fine texture), 1.5-2.0 (medium) and 2.5 (coarse). Median follow-up was 21.9 months. Primary tumors became more homogenous following chemotherapy, as entropy decreased and uniformity increased. Smaller change in skewness following chemotherapy was a significant prognostic factormedian overall survival was 36.1 months vs. 11.1 months. Lower baseline entropy and lower post-treatment MGI were also associated with improved survival, although they demonstrated only a trend toward significance.

Texture analysis of the CT scans is a post-processing step, which was done utilizing proprietary software (TexRAD) that enhances the images in ultra-fine detail not visible to the human eye. Certain tumoral features changed consistently following chemotherapy, and some features were associated with overall survival.

"Though these results are for a very small number of patients, they suggest that the tumoral texture features may provide valuable information that could help us to distinguish which patients will do well following chemotherapy and which ones will do poorly," said Connie Yip, MD, the lead study author, a clinical research fellow at King's College London, United Kingdom and an associate consultant in radiation oncology at the National Cancer Centre, Singapore. "As a biomarker for treatment efficacy, this technique could save patients from unnecessary surgery and provide more definitive guidance in developing patient treatment plans with improved outcomes."

The abstract, "CT Tumoral Heterogeneity as a Prognostic Marker in Primary Esophageal Cancer Following Neoadjuvant Chemotherapy," will be presented in detail during a scientific session at 8:00 a.m. Eastern time on Saturday, February 9, 2013. To speak with Connie Yip, MD, call Michelle Kirkwood on February 8-9, 2013, in the Press Office at the Hilton Orlando Lake Buena Vista in the Walt Disney World Resort at 407-560-2314 or email michellek@astro.org.


'/>"/>

Contact: Michelle Kirkwood
press@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Re-Analysis Refutes Diet Guidelines Favoring Vegetable Fats
2. Economic analysis finds penicillin, not "the pill," may have launched the sexual revolution
3. Canada In Vitro Diagnostics Market Analysis and Forecasts to 2017 in New Research Report at RnRMarketResearch.com
4. U.S. Medical Waste Market Analysis: Treatment, Containment, Management and Disposal Products Reviewed in New Research Report at ReportsnReports.com
5. New analysis examines stakes for Medicaid in upcoming fiscal cliff negotiations on Capitol Hill
6. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
7. Higher proportion of California children uninsured than in US, USC analysis shows
8. Steroid Shots for Sciatica: Benefits Only Brief, Analysis Finds
9. Regional analysis masks substantial local variation in health care spending
10. Millions May Be Taking Vitamin D Unnecessarily, Analysis Suggests
11. Study shows breath analysis could help diagnose pulmonary nodules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
Breaking Medicine Technology: